Preliminary data from a phase 4 post-marketing safety trial of the arthritis drug tofacitinib have turned up worrying results for the Janus kinase (JAK) inhibitor, indicating an elevated risk of causing heart problems and cancer in some patients. Read more in The Lancet Rheumatology.
tofacitinib
Tofacitinib approved for arthritis treatment in children
On Sept 28, 2020, the US Food and Drug Administration (FDA) approved Pfizer’s targeted synthetic drug tofacitinib (Xeljanz) for the treatment of polyarticular juvenile idiopathic arthritis. The drug, a Janus kinase (JAK) inhibitor, had previously been approved for use in adults with rheumatoid arthritis, but is the first in its class to be approved to […]